Information
99 Digital-ro 9-gil, Geumcheon District, Seoul, South Korea
+82 2-2144-3910
-
-
Overview
- Summary
- PCL Co., Ltd. is an in-vitro diagnostic medical device company leveraging its proprietary multi-immune diagnostic original technology. The company successfully commercialized the world's first multi-immune product for high-risk virus blood screening. It also achieved the highest grade for multi-in-vitro diagnostic medical devices in Korea and commercialized its self-developed large-scale equipment.PCL Co., Ltd. is an in-vitro diagnostic medical device company leveraging its proprietary multi-immune diagnostic original technology. The company successfully commercialized the world's first multi-immune product for high-risk virus blood screening. It also achieved the highest grade for multi-in-vitro diagnostic medical devices in Korea and commercialized its self-developed large-scale equipment.
- Key Products/Technologies
- The company possesses SG Cap™ 3D immobilization multi-diagnosis technology as its core proprietary technology. This platform offers 1000 times higher analytical sensitivity and high specificity for multiplex disease diagnosis. Its technological capability allows for simultaneous diagnosis of up to 64 diseases.The company possesses SG Cap™ 3D immobilization multi-diagnosis technology as its core proprietary technology. This platform offers 1000 times higher analytical sensitivity and high specificity for multiplex disease diagnosis. Its technological capability allows for simultaneous diagnosis of up to 64 diseases.
- Product lines include blood screening systems such as HiSU and the portable PCLOK II. HiSU is a system capable of simultaneously screening for 5 viral infections including HIV, Hepatitis C, Hepatitis B, and Syphilis in up to 540 individuals within 4 hours.Product lines include blood screening systems such as HiSU and the portable PCLOK II. HiSU is a system capable of simultaneously screening for 5 viral infections including HIV, Hepatitis C, Hepatitis B, and Syphilis in up to 540 individuals within 4 hours.
- For COVID-19 diagnostics, the company developed the 'PCL COVID 19 Ag Gold' antigen rapid diagnostic kit, utilizing both saliva and nasopharyngeal samples. This kit provides results within 10 minutes, with a clinical sensitivity of 94% and specificity of 99.99%.For COVID-19 diagnostics, the company developed the 'PCL COVID 19 Ag Gold' antigen rapid diagnostic kit, utilizing both saliva and nasopharyngeal samples. This kit provides results within 10 minutes, with a clinical sensitivity of 94% and specificity of 99.99%.
- In the field of dementia diagnostics, the company developed a high-sensitivity Alzheimer's diagnostic kit using novel markers. Product development is also underway for an influenza diagnostic product, Ai, and a multiplex cancer diagnostic product, Cancer-6.In the field of dementia diagnostics, the company developed a high-sensitivity Alzheimer's diagnostic kit using novel markers. Product development is also underway for an influenza diagnostic product, Ai, and a multiplex cancer diagnostic product, Cancer-6.
- Development of AI-based Point-of-Care Testing (POCT) technology, showcased at CES. Provision of various research platform services, including SG-ID.Development of AI-based Point-of-Care Testing (POCT) technology, showcased at CES. Provision of various research platform services, including SG-ID.
- Core Advantages
- Possession of proprietary 3D immobilization multi-diagnosis original technology (SG Cap™). This core technology enables accurate diagnosis of multiple diseases at once with high sensitivity and specificity.Possession of proprietary 3D immobilization multi-diagnosis original technology (SG Cap™). This core technology enables accurate diagnosis of multiple diseases at once with high sensitivity and specificity.
- Successful large-scale multi-center clinical trials and commercialization of the world's first multi-diagnostic reagent for high-risk viruses in blood screening. A unique position as the sole blood screening specialist in Korea.Successful large-scale multi-center clinical trials and commercialization of the world's first multi-diagnostic reagent for high-risk viruses in blood screening. A unique position as the sole blood screening specialist in Korea.
- External recognition of technological prowess, including the Minister's Award at the 2015 Korea Technology Awards (for SG Cap™-based multiplex disease diagnostic system). Acquisition of New Excellent Technology (NET) certification in 2017. Recipient of the Minister of Trade, Industry and Energy Award for 'Industrial Innovation Technology of the Year' in 2022 for its dementia diagnostic kit technology development project.External recognition of technological prowess, including the Minister's Award at the 2015 Korea Technology Awards (for SG Cap™-based multiplex disease diagnostic system). Acquisition of New Excellent Technology (NET) certification in 2017. Recipient of the Minister of Trade, Industry and Energy Award for 'Industrial Innovation Technology of the Year' in 2022 for its dementia diagnostic kit technology development project.
- Global market entry capabilities, with ongoing business in South America and Europe. Export of blood screening product Hi3-1 to France, Germany, and Brazil. A 10-year, 100 billion KRW supply contract for blood screening equipment and reagents with ASTA, Russia's largest blood center diagnostic service company. Approval and export of COVID-19 diagnostic kits to Canada, Germany, Africa, and Taiwan. Securing a foothold for expansion into African and Middle Eastern markets, including Morocco.Global market entry capabilities, with ongoing business in South America and Europe. Export of blood screening product Hi3-1 to France, Germany, and Brazil. A 10-year, 100 billion KRW supply contract for blood screening equipment and reagents with ASTA, Russia's largest blood center diagnostic service company. Approval and export of COVID-19 diagnostic kits to Canada, Germany, Africa, and Taiwan. Securing a foothold for expansion into African and Middle Eastern markets, including Morocco.
- Capability for product expansion into rapid and simple diagnostics through the development of various applied technologies. Advancement of AI-based POCT and pursuit of home healthcare market solutions. Diversification of business through the establishment of a 'One Health System' integrating human, animal, and environmental diagnostics.Capability for product expansion into rapid and simple diagnostics through the development of various applied technologies. Advancement of AI-based POCT and pursuit of home healthcare market solutions. Diversification of business through the establishment of a 'One Health System' integrating human, animal, and environmental diagnostics.
- Target Industrie
- In-vitro diagnostic medical device industryIn-vitro diagnostic medical device industry
- Bio and medical diagnostic fieldsBio and medical diagnostic fields
- Blood screening and transfusion safety testingBlood screening and transfusion safety testing
- Diagnosis of infectious diseases (e.g., HIV, hepatitis, syphilis, COVID-19, influenza)Diagnosis of infectious diseases (e.g., HIV, hepatitis, syphilis, COVID-19, influenza)
- Early diagnosis of diseases such as dementia and cancerEarly diagnosis of diseases such as dementia and cancer
- Point-of-Care Testing (POCT) marketPoint-of-Care Testing (POCT) market
- Digital healthcare, animal digital monitoring, and environmental diagnostics (future expansion areas)Digital healthcare, animal digital monitoring, and environmental diagnostics (future expansion areas)
- Major Markets
- Morocco, Other African countriesMorocco, Other African countries
- Taiwan, China (pet diagnostic products)Taiwan, China (pet diagnostic products)
- France, Germany, RussiaFrance, Germany, Russia
- Canada, United States (market entry in progress)Canada, United States (market entry in progress)
- BrazilBrazil
- Certifications/Patents
- Possession of patents related to original technology registered in over 30 countries. Notably, patents related to SG Cap™ technology.Possession of patents related to original technology registered in over 30 countries. Notably, patents related to SG Cap™ technology.
- Acquisition of the highest grade for multi-in-vitro diagnostic medical devices in Korea.Acquisition of the highest grade for multi-in-vitro diagnostic medical devices in Korea.
- Obtained CE-IVD LIST A certification (for high-risk virus diagnostic reagent Hi3-1).Obtained CE-IVD LIST A certification (for high-risk virus diagnostic reagent Hi3-1).
- Awarded the Minister's Award at the 2015 Korea Technology Awards (for 3D immobilization technology-based SG Cap™ multiplex disease diagnostic system).Awarded the Minister's Award at the 2015 Korea Technology Awards (for 3D immobilization technology-based SG Cap™ multiplex disease diagnostic system).
- Acquired New Excellent Technology (NET) certification in 2017.Acquired New Excellent Technology (NET) certification in 2017.
- Received the Minister of Trade, Industry and Energy Award for 'Industrial Innovation Technology of the Year' in 2022 (for the dementia diagnostic kit technology development project).Received the Minister of Trade, Industry and Energy Award for 'Industrial Innovation Technology of the Year' in 2022 (for the dementia diagnostic kit technology development project).
- Designated as a Youth-Friendly Small but Strong Company by the Ministry of Employment and Labor, a Family-Friendly Company by the Ministry of Gender Equality and Family, an Innobiz company, and a Seoul-type Strong Company.Designated as a Youth-Friendly Small but Strong Company by the Ministry of Employment and Labor, a Family-Friendly Company by the Ministry of Gender Equality and Family, an Innobiz company, and a Seoul-type Strong Company.
Introduction
Location
99 Digital-ro 9-gil, Geumcheon District, Seoul, South Korea
클릭하여 위치 살펴보기
